Abstract
BackgroundDenosumab (d-mab), an anti-receptor activator of nuclear factor kappa-B ligand (RANKL) monoclonal antibody, is now widely used in postmenopausal osteoporosis (OP) treatment. It can attain reliable increase of bone mineral...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have